Clinical Trial Search Results for "OPUS-TIMI 16"

Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, Lopez-Sendon J, Toman J, Charlesworth A, Anders RJ, Alexander JC, Skene A, Braunwald E. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000;102:149-56. Abstract

Cannon, C. P. Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials Clin Cardiol. 2000;23 Suppl 6(NA):VI-14-7. Abstract

Holmes, M. B., Sobel, B. E., Cannon, C. P., Schneider, D. J. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction Am J Cardiol. 2000;85(4):491-3, A10. Abstract

Cannon, C. P., McCabe, C. H., Wilcox, R. G., Bentley, J. H., Braunwald, E. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators Am J Cardiol. 2001;87(5):636-9, A10. Abstract

O'Connor, F. F., Shields, D. C., Fitzgerald, A., Cannon, C. P., Braunwald, E., Fitzgerald, D. J. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes Blood. 2001;98(12):3256-60. Abstract

de Lemos, J. A., Morrow, D. A., Bentley, J. H., Omland, T., Sabatine, M. S., McCabe, C. H., Hall, C., Cannon, C. P., Braunwald, E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes N Engl J Med. 2001;345(14):1014-21. Abstract

Brassard, J. A., Curtis, B. R., Cooper, R. A., Ferguson, J., Komocsar, W., Ehardt, M., Kupfer, S., Maurath, C., Swabb, E., Cannon, C. P., Aster, R. H. Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology Thromb Haemost. 2002;88(6):892-7. Abstract

Kenny, D., Muckian, C., Fitzgerald, D. J., Cannon, C. P., Shields, D. C. Platelet glycoprotein Ib alpha receptor polymorphisms and recurrent ischaemic events in acute coronary syndrome patients J Thromb Thrombolysis. 2002;13(1):13-9. Abstract

Shields, D. C., Fitzgerald, A. P., O'Neill, P. A., Muckian, C., Kenny, D., Moran, B., Cannon, C. P., Byrne, C. E., Fitzgerald, D. J. The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists Pharmacogenomics J. 2002;2(3):182-90. Abstract

Cotter, G., Cannon, C. P., McCabe, C. H., Michowitz, Y., Kaluski, E., Charlesworth, A., Milo, O., Bentley, J., Blatt, A., Krakover, R., Zimlichman, R., Reisin, L., Marmor, A., Lewis, B., Vered, Z., Caspi, A., Braunwald, E. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study Am Heart J. 2003;145(4):622-7. Abstract

Morrow, D. A., Rifai, N., Sabatine, M. S., Ayanian, S., Murphy, S. A., de Lemos, J. A., Braunwald, E., Cannon, C. P. Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes Clin Chem. 2003;49(8):1396-8.

Serrano, C. V., Jr., Nicolau, J. C., Venturinelli, M., Baracioli, L. M., Anders, R. J., Cannon, C. P., Ramires, J. A. Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes Cardiovasc Drugs Ther. 2003;17(2):129-32. Abstract

Varo, N., de Lemos, J. A., Libby, P., Morrow, D. A., Murphy, S. A., Nuzzo, R., Gibson, C. M., Cannon, C. P., Braunwald, E., Schonbeck, U. Soluble CD40L: risk prediction after acute coronary syndromes Circulation. 2003;108(9):1049-52. Abstract

de Lemos, J. A., Morrow, D. A., Sabatine, M. S., Murphy, S. A., Gibson, C. M., Antman, E. M., McCabe, C. H., Cannon, C. P., Braunwald, E. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes Circulation. 2003;107(5):690-5. Abstract

Byrne, C. E., Fitzgerald, A., Cannon, C. P., Fitzgerald, D. J., Shields, D. C. Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes BMC Med Genet. 2004;5(NA):13. Abstract

Kovar, D., Cannon, C. P., Bentley, J. H., Charlesworth, A., Rogers, W. J. Does initial and delayed heart rate predict mortality in patients with acute coronary syndromes? Clin Cardiol. 2004;27(2):80-6. Abstract

Wylie, J. V., Murphy, S. A., Morrow, D. A., de Lemos, J. A., Antman, E. M., Cannon, C. P. Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18 Am Heart J. 2004;148(1):173-80. Abstract

Cantor, W. J., Goodman, S. G., Cannon, C. P., Murphy, S. A., Charlesworth, A., Braunwauld, E., Langer, A. Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial Am Heart J. 2005;149(2):275-83. Abstract

Gurjeva, O. S., Bukhman, G., Murphy, S., Cannon, C. P. Treatment and outcomes of eastern Europeans with coronary syndromes in OPUS-TIMI 16 Int J Cardiol. 2005;100(1):101-7. Abstract

Kirtane, A. J., Leder, D. M., Waikar, S. S., Chertow, G. M., Ray, K. K., Pinto, D. S., Karmpaliotis, D., Burger, A. J., Murphy, S. A., Cannon, C. P., Braunwald, E., Gibson, C. M. Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates J Am Coll Cardiol. 2005;45(11):1781-6. Abstract

Smith, C. S., Cannon, C. P., McCabe, C. H., Murphy, S. A., Bentley, J., Braunwald, E. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial Am Heart J. 2005;149(3):444-50. Abstract

Atar, S., Cannon, C. P., Murphy, S. A., Rosanio, S., Uretsky, B. F., Birnbaum, Y. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial Am Heart J. 2006;151(5):976 e1-6. Abstract

Bhadriraju, S., Ray, K. K., DeFranco, A. C., Barber, K., Bhadriraju, P., Murphy, S. A., Morrow, D. A., McCabe, C. H., Gibson, C. M., Cannon, C. P., Braunwald, E. Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial Am J Cardiol. 2006;97(11):1573-7. Abstract

O'Donoghue, M., de Lemos, J. A., Morrow, D. A., Murphy, S. A., Buros, J. L., Cannon, C. P., Sabatine, M. S. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes Circulation. 2006;114(6):550-7. Abstract

Scirica, B. M., Cannon, C. P., Cooper, R., Aster, R. H., Brassard, J., McCabe, C. H., Charlesworth, A., Skene, A. M., Braunwald, E. Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial J Thromb Thrombolysis. 2006;22(2):95-102. Abstract

Smith, E. E., Cannon, C. P., Murphy, S., Feske, S. K., Schwamm, L. H. Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study Am Heart J. 2006;151(2):338-44. Abstract

Matheny, M. E., Morrow, D. A., Ohno-Machado, L., Cannon, C. P., Resnic, F. S. Validating an automated outcomes surveillance application using data from a terminated randomized, controlled trial (OPUS [TIMI-16]) AMIA Annu Symp Proc. 2007;NA(NA):1043. Abstract

Ray, K. K., Cannon, C. P., Morrow, D. A., Kirtane, A. J., Buros, J., Rifai, N., McCabe, C. H., Gibson, C. M., Braunwald, E. Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18 Eur Heart J. 2007;28(7):806-13. Abstract

Mega, J. L., Morrow, D. A., de Lemos, J. A., Mohanavelu, S., Cannon, C. P., Sabatine, M. S. Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes J Am Coll Cardiol. 2008;51(25):2422-9. Abstract

Olenchock, B. A., Wiviott, S. D., Murphy, S. A., Cannon, C. P., Rifai, N., Braunwald, E., Morrow, D. A. Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16 J Thromb Thrombolysis. 2008;26(2):79-84. Abstract

Maree, A. O., Vangjeli, C., Jneid, H., Ryan, J., Cox, D., Cannon, C. P., Shields, D. C., Fitzgerald, D. J. G-protein beta3 subunit polymorphism and bleeding in the orbofiban in patients with unstable coronary syndromes-thrombolysis in myocardial infarction 16 trial J Thromb Haemost. 2010;8(5):934-41. Abstract

Steen, Dylan L., Cannon, Christopher P., Lele, Suhas S., Rajapurkar, Mohan M., Mukhopadhyay, Banibrata, Scirica, Benjamin M., Murphy, Sabina A., Morrow, David A. Prognostic Evaluation of Catalytic Iron in Patients With Acute Coronary Syndromes Clinical Cardiology. 2013;NA(NA):n/a-n/a.